Come walk with us down the
CYPRESS path

This research study is testing an investigational drug (ampreloxetine) compared to placebo in people with MSA and symptomatic nOH. It will help answer the following questions:

• How effective is ampreloxetine in treating people with MSA and nOH?
• How safe is ampreloxetine and are there unwanted side effects?

You can talk to a study doctor to find out if you may qualify for the study. Contact us at cypress@theravance.com or by calling +1-855-633-8479.

There is no cost to participate in the CYPRESS study. The investigational drug, study-related tests, assessments, and study visits will be provided at no cost to you and your insurance company. If you decide to take part in the study, you will receive study-related care throughout the study from a team of experienced doctors and nurses.

No health insurance is required to participate.

Volunteers who take part in the study may be compensated for travel costs and time in the study. Please discuss this with the study site when you are in contact with them.

The research team at your study site will be able to explain more about what the CYPRESS study will involve, and it is up to you to decide if you want to participate. Participation in this study is voluntary. Whether or not you decide to participate in this study will not affect your current or future relationships with your doctors. If you decide to participate, you are free to withdraw at any time without affecting those relationships.

There are risks and benefits of taking part in any clinical study. For example, your health may be more closely monitored than it would have been otherwise. You may or may not benefit from the investigational drug (ampreloxetine). It is not known if your condition will get any better; it may get worse. This study is being conducted to learn more about the investigational drug. What we learn may help other MSA patients in the future. The known risks and benefits of participation are outlined in the informed consent form (ICF) that you must read and sign before you can take part in this study. You should also discuss this question with your physician.

Please contact us to explore further options; we are committed to supporting participants with travel logistics and expenses necessary to participate in the study.

The clinical study has 9 visits over approximately 20 weeks. If you continue in the (optional) long-term extension study, there are 2 additional visits.

Participants in the CYPRESS study are restricted from participating in other studies in which they receive an investigational drug. Participation in an observational study that does not require interventional treatment (e.g., another study drug from a different trial) is permitted.

The investigational drug (ampreloxetine) was assessed in a study that had a similar design to the CYPRESS study. In that study, in a pre-specified population of participants with MSA, there was a durable and clinically meaningful improvement in their nOH symptoms. The results of this study are available on the Theravance Biopharma website. We are running the Phase 3 CYPRESS study to confirm whether the results of the prior trial are replicable in a larger group of patients.